Global transcriptional analysis for biomarker discovery and validation in cellular therapies

David F. Stroncek, Ping Jin, Ena Wang, Jiagiang Ren, Marianna Sabatino, Francesco M. Marincola

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Potency testing is an important part of the evaluation of cellular therapy products. Potency assays are quantitative measures of a product-specific biologic activity that is linked to a relevant biologic property and, ideally, a product's in vivo mechanism of action. Both in vivo and in vitro assays can be used for potency testing. Since there is often a limited period of time between the completion of production and the release from the laboratory for administration to the patient, in vitro assays such as flow cytometry, ELISA, and cytotoxicity are typically used. Better potency assays are needed to assess the complex and multiple functions of cellular therapy products, some of which are not well understood. Gene expression profiling using microarray technology has been widely and effectively used to assess changes of cells in response to stimuli and to classify cancers. Preliminary studies have shown that the expression of non-coding microRNA (miRNA), which plays an important role in cellular development, differentiation, metabolism, and signal transduction, can distinguish between different types of stem cells and leukocytes. Both gene and miRNA expression profiling have the potential to be important tools for testing the potency of cellular therapies. Potency testing, the complexities associated with potency testing of cellular therapies, and the potential role of gene and miRNA expression microarrays in potency testing of cellular therapies are discussed.

Original languageEnglish
Pages (from-to)181-193
Number of pages13
JournalMolecular Diagnosis and Therapy
Volume13
Issue number3
DOIs
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

Biomarkers
MicroRNAs
Gene Expression Profiling
Therapeutics
Biological Products
Signal Transduction
Flow Cytometry
Leukocytes
Stem Cells
Enzyme-Linked Immunosorbent Assay
Technology
Gene Expression
Neoplasms
In Vitro Techniques

ASJC Scopus subject areas

  • Genetics
  • Molecular Medicine
  • Medicine(all)
  • Pharmacology

Cite this

Global transcriptional analysis for biomarker discovery and validation in cellular therapies. / Stroncek, David F.; Jin, Ping; Wang, Ena; Ren, Jiagiang; Sabatino, Marianna; Marincola, Francesco M.

In: Molecular Diagnosis and Therapy, Vol. 13, No. 3, 2009, p. 181-193.

Research output: Contribution to journalReview article

Stroncek, David F. ; Jin, Ping ; Wang, Ena ; Ren, Jiagiang ; Sabatino, Marianna ; Marincola, Francesco M. / Global transcriptional analysis for biomarker discovery and validation in cellular therapies. In: Molecular Diagnosis and Therapy. 2009 ; Vol. 13, No. 3. pp. 181-193.
@article{5166773b4fe54ee6bfcbad8cae18b5cf,
title = "Global transcriptional analysis for biomarker discovery and validation in cellular therapies",
abstract = "Potency testing is an important part of the evaluation of cellular therapy products. Potency assays are quantitative measures of a product-specific biologic activity that is linked to a relevant biologic property and, ideally, a product's in vivo mechanism of action. Both in vivo and in vitro assays can be used for potency testing. Since there is often a limited period of time between the completion of production and the release from the laboratory for administration to the patient, in vitro assays such as flow cytometry, ELISA, and cytotoxicity are typically used. Better potency assays are needed to assess the complex and multiple functions of cellular therapy products, some of which are not well understood. Gene expression profiling using microarray technology has been widely and effectively used to assess changes of cells in response to stimuli and to classify cancers. Preliminary studies have shown that the expression of non-coding microRNA (miRNA), which plays an important role in cellular development, differentiation, metabolism, and signal transduction, can distinguish between different types of stem cells and leukocytes. Both gene and miRNA expression profiling have the potential to be important tools for testing the potency of cellular therapies. Potency testing, the complexities associated with potency testing of cellular therapies, and the potential role of gene and miRNA expression microarrays in potency testing of cellular therapies are discussed.",
author = "Stroncek, {David F.} and Ping Jin and Ena Wang and Jiagiang Ren and Marianna Sabatino and Marincola, {Francesco M.}",
year = "2009",
doi = "10.2165/01250444-200913030-00003",
language = "English",
volume = "13",
pages = "181--193",
journal = "Molecular Diagnosis and Therapy",
issn = "1177-1062",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Global transcriptional analysis for biomarker discovery and validation in cellular therapies

AU - Stroncek, David F.

AU - Jin, Ping

AU - Wang, Ena

AU - Ren, Jiagiang

AU - Sabatino, Marianna

AU - Marincola, Francesco M.

PY - 2009

Y1 - 2009

N2 - Potency testing is an important part of the evaluation of cellular therapy products. Potency assays are quantitative measures of a product-specific biologic activity that is linked to a relevant biologic property and, ideally, a product's in vivo mechanism of action. Both in vivo and in vitro assays can be used for potency testing. Since there is often a limited period of time between the completion of production and the release from the laboratory for administration to the patient, in vitro assays such as flow cytometry, ELISA, and cytotoxicity are typically used. Better potency assays are needed to assess the complex and multiple functions of cellular therapy products, some of which are not well understood. Gene expression profiling using microarray technology has been widely and effectively used to assess changes of cells in response to stimuli and to classify cancers. Preliminary studies have shown that the expression of non-coding microRNA (miRNA), which plays an important role in cellular development, differentiation, metabolism, and signal transduction, can distinguish between different types of stem cells and leukocytes. Both gene and miRNA expression profiling have the potential to be important tools for testing the potency of cellular therapies. Potency testing, the complexities associated with potency testing of cellular therapies, and the potential role of gene and miRNA expression microarrays in potency testing of cellular therapies are discussed.

AB - Potency testing is an important part of the evaluation of cellular therapy products. Potency assays are quantitative measures of a product-specific biologic activity that is linked to a relevant biologic property and, ideally, a product's in vivo mechanism of action. Both in vivo and in vitro assays can be used for potency testing. Since there is often a limited period of time between the completion of production and the release from the laboratory for administration to the patient, in vitro assays such as flow cytometry, ELISA, and cytotoxicity are typically used. Better potency assays are needed to assess the complex and multiple functions of cellular therapy products, some of which are not well understood. Gene expression profiling using microarray technology has been widely and effectively used to assess changes of cells in response to stimuli and to classify cancers. Preliminary studies have shown that the expression of non-coding microRNA (miRNA), which plays an important role in cellular development, differentiation, metabolism, and signal transduction, can distinguish between different types of stem cells and leukocytes. Both gene and miRNA expression profiling have the potential to be important tools for testing the potency of cellular therapies. Potency testing, the complexities associated with potency testing of cellular therapies, and the potential role of gene and miRNA expression microarrays in potency testing of cellular therapies are discussed.

UR - http://www.scopus.com/inward/record.url?scp=68549096121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68549096121&partnerID=8YFLogxK

U2 - 10.2165/01250444-200913030-00003

DO - 10.2165/01250444-200913030-00003

M3 - Review article

C2 - 19650671

AN - SCOPUS:68549096121

VL - 13

SP - 181

EP - 193

JO - Molecular Diagnosis and Therapy

JF - Molecular Diagnosis and Therapy

SN - 1177-1062

IS - 3

ER -